Key features and details
- Rabbit polyclonal to Vaccinia Virus (Biotin)
- Suitable for: ELISA
- Reacts with: Vaccinia virus
- Conjugation: Biotin
- Isotype: IgG
Product nameAnti-Vaccinia Virus antibody (Biotin)
See all Vaccinia Virus primary antibodies
DescriptionRabbit polyclonal to Vaccinia Virus (Biotin)
Tested applicationsSuitable for: ELISAmore details
Species reactivityReacts with: Vaccinia virus
Lister Strain (mixture of virions and infected cell polypeptides).
The antibody is covalently coupled with the N-Hydroxysuccinimide ester of biotin under mild conditions to give a high degree of substitution.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.1% Sodium azide
Constituent: 0.0268% PBS
Concentration information loading...
Our Abpromise guarantee covers the use of ab21039 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use at an assay dependent dilution.|
RelevanceVaccinia virus is an Orthopoxvirus, containing double stranded DNA. Fusion protein plays an important role in the entry of enveloped virus into cells. As vaccinia virus has a wide host range, it is conceivable that certain cellular components that are ubiquitously expressed on the cell mediate virus infection. The study of the entry process, attachment, fusion and the proteins and receptors involved is complex. During vaccinia virus infection, the fusion process is attributed to the action of the 14KDa protein (A27L). The N terminus of this protein recognises heparan sulfate on the cell surface. It interacts with the negative charges of sulfates of glycosaminoglycans (GAGs). Therefore, antibodies that recognize this 14KDa protein are able to neutralize vaccinia virus infection and enable identification other viral and cellular proteins which participate in the vaccinia virus entry process.
- A27L antibody
- Orthopoxvirus antibody
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab21039 has been referenced in 1 publication.
- Ylösmäki E et al. Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses. Mol Ther 26:2315-2325 (2018). PubMed: 30005865